吉利德科學 GILD 深 滬
已收盤 12-12 16:00:00 美东时间
120.40
-2.810
-2.28%
華盛通- 最 高123.625
- 今 開122.86
- 成交量 676.78万股
- 最 低 119.53
- 昨 收 123.21
- 總市值 1494.16亿
- 52周最高 128.70
- 市盈率 靜 314.77
- 換手率 0.55%
- 52周最低 86.20
- 委 比 87.31%
- 總股本 12.41亿
- 歷史最高 128.70
- 量 比 0.85
- 振 幅 3.32%
- 歷史最低 7.51
- 每 手 1
- 風險率 10.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC data and key 2026 milestones.
12-13 02:35
Arcus Biosciences Discontinues Phase 3 STAR-221 Study With Gilead Following IDMC Futility Recommendation
The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futilityArcus is continuing to expand its development program for casdatifan, a
12-12 21:33
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
12-11 10:33
Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $150
Wells Fargo analyst Mohit Bansal maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $145 to $150.
12-11 04:06
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
Ligand Pharmaceuticals provided its 2026 financial guidance, anticipating revenue of $245 million to $285 million, a 15% core revenue growth over 2025, with royalty revenue projected at $200 million to $225 million, a 40% increase. The company also expects core adjusted earnings per diluted share of $8.00 to $9.00. Ligand highlighted strong performances in 2025, driven by a 40% increase in royalty revenue and a 30% rise in core adjusted earnings ...
12-09 12:00
Why Is Arcellx Stock Surging Today?
Arcellx shares updated ASH data showing strong response and survival results for anito-cel in relapsed multiple myeloma, with analysts highlighting its emerging profile.
12-09 02:23
美联储议息前瞻：鲍威尔“圣诞大礼”将至！降息25基点助力美股再创新高？
美股再冲新高之际，市场押注本周降息25基点板上钉钉，这项关键数据将暗示“圣诞行情”能否如期而至。投资者如何抢跑布局？一文看懂>>
12-08 19:22
体内CAR-T，MNC选定的「进化之路」
原标题：体内CAR-T，MNC选定的「进化之路」 来源：锦缎 沉寂许久的CAR-T赛道终于起风了。最近两年，MNC频繁对体内CAR-T资产出手，累计完成超5...
12-05 10:51
Soleno Therapeutics Announces the Passing of Board Member William G. Harris
Soleno Therapeutics announce the passing of Bill Harris, a valued Board member and Audit Committee Chairman since 2014. Harris, known for his integrity and expertise, had a prominent career in biopharmaceutical finance. Andrew Sinclair, a long-serving Board member, will assume the Audit Committee Chair position. Soleno focuses on rare disease therapeutics, with its FDA-approved VYKAT™ XR for Prader-Willi syndrome hyperphagia.
12-03 21:05
特朗普亲自点名！美联储主席已“内定”哈塞特？这些港美股交易值得提前布局
当选美联储主席概率已达86%！哈塞特持股Coinbase超百万美元，除了加密市场外，若哈塞特上任后还利好哪些港美股？一文看懂>>
12-03 16:26
